Skip to main content
SpringerLink
Log in

Biology, Staging and Treatment of Hodgkin’s Disease

  • Conference paper
Book cover Malignant Lymphomas: Biology and Treatment

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 39 Accesses

Abstract

Hodgkin’s disease, first described by Thomas Hodgkin (1798–1866), is a malignant disease characterized by the presence of Hodgkin and Reed-Stemberg giant cells (H-RS). In the tissues involved, H-RS cells are usually sparse and surrounded by a variety of reactive “by-stander” cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Glaser SL: Hodgkin’s disease in black populations: A review of the epidemiologic literature. Sem Oncol 1990 (6):643–659

    Google Scholar 

  2. Diehl V, von Kalle C, Fonatsch C, Tesch H, Jücker M, Schaadt M: The cell of origin of Hodgkin’s disease. Sem Oncol 1991 (17):660–672

    Google Scholar 

  3. Diehl V, Kirchner HH, Schaadt H et al: Hodgkin’s disease: establishment and characterization of four in vitro cell lines. J Cancer Res Clin Oncol 1981 (101):111–124

    Article  PubMed  CAS  Google Scholar 

  4. Stein H, Mason DY, Gerdes J et al: The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985 (4):848–856

    Google Scholar 

  5. Dürkop H, Latza U, Hummel M et al: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992 (68):421–427

    Article  PubMed  Google Scholar 

  6. Kadin M: The Reed-Sternberg cell, an activated T-cell? The evidence has come full circle. Leukemia and Lymphoma Reviews 1992 (1):281–288

    Google Scholar 

  7. Poppema S, van Imhoff G, Torensma R et al: Lym-phadenopathy morphologically consistent with Hodgkin’s disease associated with EBV infection. Am J Clin Pathol 1985 (84):385–390

    PubMed  CAS  Google Scholar 

  8. Gruss HJ, Brach MA, Drexler HG et al: Interleukin 9 Is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992 (52):1026–1031

    PubMed  CAS  Google Scholar 

  9. Kapp U, Wolf J, von Kalle C et al: Growth of Hodgkin’s lymphoma derived cell lines in immune compromised mice. Ann Oncol 1992 (3 suppl 4):21–24

    PubMed  Google Scholar 

  10. Mueller N, Evans A, Harris NL et al: Hodgkin’s disease and Epstein-Barr virus. N Engl J Med 1989 (320):689–692

    Article  PubMed  CAS  Google Scholar 

  11. Herbst H, Steinbrecher E, Nidobitek G et al: Distribution and phenotype of EBV-harboring cells in Hodgkin’s disease. Blood 1992 (80): in press

    Google Scholar 

  12. Trümper LH, Brady G, Vicini S, Cossman J, Mak TW: Gene expression in single Reed Sternberg cells of Hodgkin’s disease: Results from PCR generated single cell cDNA libraries. Ann Oncol 1992 (3 suppl 4):25–26

    PubMed  Google Scholar 

  13. Gause A, Jung W, Schmits R et al: Soluble CD8, CD25 and CD30 antigen as prognostic markers in patients with untreated Hodgkin’s lymphoma. Ann Oncol 1992 (3 suppl 4): 49–52

    PubMed  Google Scholar 

  14. Stein H, Schwarting R, Dallenbach F, Dienemann D: Immunology of Hodgkin and Reed-Sternberg cells. Rec Res Cancer Res 1989 (117):14–27

    CAS  Google Scholar 

  15. Lukes RJ, Butler JJ, Hicks EB: Natural history of Hodgkin’s disease is related to its pathologic picture. Cancer 1966 (19):317–344

    Article  Google Scholar 

  16. Hansmann ML, Wacker HH, Radzun HJ: Paragranuloma is a variant of Hodgkin’s disease with predominance of B-cells. Virchows Arch A 1986 (409):171–181

    Article  CAS  Google Scholar 

  17. MacLennan K A, Bennet MH, Ru A et al: Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. Cancer 1989 (64):1686–1693

    Article  PubMed  CAS  Google Scholar 

  18. Loeffler M, Mauch P, MacLennan K, Specht L, Henry-Amar M: Review on prognostic factors. Ann Oncol 1992 (3 suppl 4): 63–66

    Google Scholar 

  19. Kaplan HS: Hodgkin’s disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 1980 (45):2439–1474

    Article  PubMed  CAS  Google Scholar 

  20. Horning SJ, Hoppe RT, Hancock SL et al. Vinblastine, bleomycin and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 1988 (6):1822–1831

    PubMed  CAS  Google Scholar 

  21. Mauch P, Larson D, Osteen R et al: Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 1990 (2):257–265

    Google Scholar 

  22. Henry-Amar M: Second cancer after the treatment for Hodgkin’s disease: A report from the International Database on Hodgkin’s disease. Ann Oncol 1992 (3 suppl 4):117–128

    PubMed  Google Scholar 

  23. Hellman S, Jaffa ES, DeVita VT: Hodgkin’s Disease. Lippincott Company, Philadelphia 1989 pp 1696–1740

    Google Scholar 

  24. Bonadonna G and Santoro A: ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 1982 (9):21–35

    Article  PubMed  CAS  Google Scholar 

  25. Bonadonna G, Valagussa P, Santorano A: Alternating non-cross-resistant combination or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 1986 (104):739–746

    PubMed  CAS  Google Scholar 

  26. Klimo P and Connors JM: An update on the Vancouver experience in the management of advanced Hodgkin’s disease treated with the MOPP/ABV hybrid program. Sem Hematol 1988 (25):34–40

    CAS  Google Scholar 

  27. Connors JM: MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin’s disease. Proc ASCO 1992 (11):1073a

    Google Scholar 

  28. Diehl V: Dose escalation study for the treatment of Hodgkin’s disease. Ann Hematol 1992 (66):139–140

    Article  Google Scholar 

  29. Kreuser ED, Felsenberg D, Behles C et al: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin’s disease. Ann Oncol 1992 (3 suppl 4):105–110

    PubMed  Google Scholar 

  30. Valagussa P, Santoro A, Bonadonna G: Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin’s disease. Ann Oncol 1992 (3 suppl 4):111–116

    PubMed  Google Scholar 

  31. Engert A, Pohl C, Diehl V: Experimental therapy in Hodgkin’s disease. Ann Oncol 1992 (3 suppl 4):97–100

    PubMed  Google Scholar 

  32. Engert A, Burrows F, Jung W et. al: Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin’s disease. Cancer Res 1990 (50): 84–88

    PubMed  CAS  Google Scholar 

  33. Falini B, Bolognesi A, Flenghi L et al: Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet 1992 (339): 1195

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Universität zu Köln, Joseph-Stelzmann-Straße 9, 5000, Köln 41, Germany

    Ulrich Rüffer, Markus Sieber, Hans Tesch, Andreas Engert & Volker Diehl

Authors
  1. Ulrich Rüffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Sieber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Tesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Volker Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National and Kapodistrian University of Greece School of Medicine Laikon General Hospital, Athens, 115 27, Greece

    Gerassimos Alexander Pangalis (Associate Professor in Haematology and Medicine, Visiting Clinical Associate Professor) (Associate Professor in Haematology and Medicine, Visiting Clinical Associate Professor)

  2. School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA

    Gerassimos Alexander Pangalis (Associate Professor in Haematology and Medicine, Visiting Clinical Associate Professor) (Associate Professor in Haematology and Medicine, Visiting Clinical Associate Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rüffer, U., Sieber, M., Tesch, H., Engert, A., Diehl, V. (1995). Biology, Staging and Treatment of Hodgkin’s Disease. In: Pangalis, G.A. (eds) Malignant Lymphomas: Biology and Treatment. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79913-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79913-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79915-0

  • Online ISBN: 978-3-642-79913-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation